Rajiv De Silva Named President and CEO of Endo Health Solutions

       Rajiv De Silva Named President and CEO of Endo Health Solutions

Brings Extensive Leadership And Operations Experience in Healthcare Industry

PR Newswire

MALVERN, Pa., Feb. 25, 2013

MALVERN, Pa., Feb. 25, 2013 /PRNewswire/ --Endo Health Solutions Inc.
(Nasdaq: ENDP) today announced that Rajiv De Silva, a pharmaceutical executive
who had been President of Valeant Pharmaceuticals and a senior executive at
Novartis, has been named Endo's President and Chief Executive Officer,
effective March 18. Mr. De Silva, who will also join the Endo Board of
Directors, succeeds David Holveck who is retiring.

"Rajiv is a strong leader with the deep industry experience, outcome-oriented
approach, and proven ability to drive results the Board was seeking in our
next CEO," said Roger H. Kimmel, Chairman of the Board. "His track record in
generating growth and profitability, managing complex integrations, and
delivering for shareholders will serve us well. We are focused on taking the
actions needed to create value for Endo shareholders and believe today's
announcement is another key step forward that will enable us to build on
Endo's strong foundation. At the same time, we appreciate Dave Holveck's
significant contributions to Endo, including his leadership in reducing the
Company's dependence on Lidoderm, and wish him well in his retirement."

Said De Silva, "I am excited to take on the challenge of leading Endo and
helping the Company realize its full potential. Endo occupies a unique
position in the healthcare market, able to deliver innovative products and
services across multiple platforms with clear strengths in the medically
important areas of pain management and urology. I look forward to working
with the Endo team to build on its strengths and deliver top line growth while
also improving cost management, execution and integration to enable Endo to
make the most of its many opportunities and create value for its
shareholders."

Mr. De Silva, 46, has deep experience in the pharmaceutical sector. He most
recently served as President of Valeant Pharmaceuticals, a $20 billion market
capitalization specialty pharmaceutical company with a presence in the U.S.
and a wide range of international markets. While at Valeant from 2009 to
2013, Mr. De Silva also served as Chief Operating Officer of Valeant's
Specialty Pharmaceuticals business. During this period, he drove a turnaround
plan that resulted in a multi-fold increase in revenues through acquisitions
and organic sales growth, substantial improvements in profitability and cash
flow generation, and put Valeant among the leading creators of shareholder
value in the sector.

Prior to joining Valeant, Mr. De Silva was a senior executive at Novartis from
2003 to 2008, most recently serving as President of its Vaccines business in
the U.S. and the Head of Vaccines in the Americas. He was previously
President and CEO of Novartis Pharmaceuticals Canada and Global Head of
Strategic Planning for Novartis Pharma. Earlier in his career, he was a
Principal at McKinsey & Company, where he served as a member of the
partnership group that led the global Pharmaceutical and Medical Products
practice.

He currently serves on the Board of AMAG Pharmaceuticals, a publicly traded
specialty pharmaceutical company focused on nephrology, hematology, and
oncology, where he is a member of the Audit and Transaction committees. He
holds a Bachelor of Science in civil engineering from Princeton University, a
Masters of Science in civil engineering from Stanford University, and a
Masters of Business Administration from the University of Pennsylvania's
Wharton School.

Conference Call and Webcast

Endo will host a conference call and webcast at 4:30 p.m. ET today. Investors
and other interested parties may call (866)578-5771 (domestic) or (617)
213-8055 (international) and enter passcode 10495594. Please dial in 10
minutes prior to the scheduled start time.

A replay of the call will be available from February 25, 2013 at 6:30pm ET
until 11:59pm ET on March 4, 2013 by dialing (888) 286-8010 (domestic) or
(617) 801-6888 (international) and entering passcode 57765730.

A simultaneous webcast of the call may be accessed by visiting www.endo.com.
In addition, a replay of the webcast will be available until 12:00pm ET on
February 25, 2014. The replay can be accessed by clicking on "Events" in the
Investor Relations section of the website.

About Endo

Endo Health Solutions Inc. (Endo) is a US-based diversified healthcare company
that is redefining healthcare value by finding solutions for the unmet needs
of patients along care pathways for pain management, pelvic health, urology,
endocrinology and oncology. Through our operating companies: AMS, Endo
Pharmaceuticals, HealthTronics and Qualitest, Endo is dedicated to improving
care through a combination of branded products, generics, devices, technology
and services that creates value for patients, providers and payers alike.
Learn more at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements including
words such as "believes," "expects," "anticipates," "intends," "estimates,"
"plan," "will," "may," "look forward," "intend," "guidance," "future" or
similar expressions are forward-looking statements. Because these statements
reflect our current views, expectations and beliefs concerning future events,
these forward-looking statements involve risks and uncertainties. Investors
should note that many factors, as more fully described under the caption "Risk
Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities
and Exchange Commission and as otherwise enumerated herein or therein, could
affect our future financial results and could cause our actual results to
differ materially from those expressed in forward-looking statements contained
in our Annual Report on Form 10-K. The forward-looking statements in this
press release are qualified by these risk factors. These are factors that,
individually or in the aggregate, could cause our actual results to differ
materially from expected and historical results. We assume no obligation to
publicly update any forward-looking statements, whether as a result of new
information, future developments or otherwise.

SOURCE Endo Health Solutions Inc.

Website: http://www.endo.com
Contact: Investors/Media: Blaine Davis, +1-484-216-7158, or Investors:
Jonathan Neely, +1-484-216-6645
 
Press spacebar to pause and continue. Press esc to stop.